Virology and Immunology of Hepatitis Viruses

  • Authors: Raymond T. Chung, MD; Esperance Anne Kreek Schaefer, MD, MPH (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/10/18 (What's New)

Summary

  • Therapy for HBV infection currently includes peginterferon and nucleos(t)ide analogues that inhibit HBV polymerase[Terrault 2018; EASL HBV]
  • Peginterferon alfa-2a is administered for 48 weeks and leads to a 32% chance of HBeAg seroconversion and a 3% chance of HBsAg loss[EASL HBV]
    • A subset of patients will require retreatment

Action required